Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?
New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.
You may also be interested in...
The latest drug development news and highlights from our Performance Tracker.
Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.
Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.